SeouLin Bioscience to Distribute Cellular Dynamics' Products in Korea

Cellular Dynamics International, Inc. (CDI) has announced an exclusive agreement with SeouLin Bioscience Co., Ltd., for the distribution of CDI's products in the Republic of Korea.

Under the terms of the agreement, SeouLin Bioscience will distribute CDI’s iCell® catalog of products. CDI’s iCell products are human induced pluripotent stem cell (iPSC)-derived tissue cells, including cardiomyocytes, hepatocytes, and neurons, among others totaling up to 12 cell types, as well as special media if required. Under discussion is the expansion to distribute the MyCell® catalog of products.

CDI’s MyCell Products enable researchers to better understand the phenotypic underpinnings of a disease of interest, as they submit donor samples to CDI for the manufacture of iPSCs and tissue cells from them.

In addition, MyCell Products are already available for diseases such as cardiac arrhythmias, Alzheimer’s and Parkinson’s diseases, drug-induced liver injury, and muscular dystrophies.

As part of the agreement, SeouLin Bioscience will handle first-level technical support inquiries from its customers. Financial terms were not disclosed.

Kaz Hirao, CEO of Cellular Dynamics, said, “Our aim is to make iPSC technology widely available to researchers worldwide and thus advance biological research leading to cellular therapies and drug discovery. Korea is an attractive market to us, because it offers a regulatory environment that seeks to accelerate the development and commercialization of regenerative medicine products. We believe that SeouLin BioScience is the optimal partner for CDI, because its multi-channel distribution infrastructure provides an already developed customer base with faster access to CDI’s products and support.”